SCP-8141
Unknown
?
low confidence
SCP-8141
Expected annual
$7.3M
One-time setup
$11.7M
Annual recurring
$7.2M
Personnel
19
One-time startup costs are dominated by research buildout, reagent stockpiling, and contingency reserves (~$11.7M). Recurring annual costs (~$7.16M/year) are driven by emergency/tactical readiness, protocol GYRUS operational allocation, lab operations and specialist staff wages.
One-Time Capital Costs
Total: $11.7M
Annual Recurring Costs
Total: $7.2M/yr
Cost Scenarios
📊
Baseline
(baseline)
$7.2M/yr
Normal year with routine operations, no major tangent activations beyond expected exercises; only recurring costs incurred.
no major tangents
routine training and maintenance
🚨
Minor Incident
$7.7M/yr
Localized tangent/thaumaturgical incident requiring limited GYRUS activation, reagent consumption, and emergency response deployment.
single tangent event
emergency tactical activation
reagent resupply
🚨
Major Breach
$9.2M/yr
Sustained tangent reality breach requiring multi-site coordination, extended remediation, and replacement of specialized equipment/reagents.
multi-day tangent
cross-site GYRUS mobilization
equipment/reagent replacement
🚨
Catastrophic Breach
$13.2M/yr
Severe or multiple concurrent tangent breaches causing facility damage, major containment escalation, and invocation of neutralization/containment contingency.
prolonged / concurrent tangents
facility damage
containment escalation / neutralization
Personnel
19 total
| Role | Count | Notes |
|---|---|---|
| Research Scientist / Chief of Applied Occultism | 1 | [#1] Senior researcher / mission-critical thaumaturge (salary & benefits included in staff_wages). |
| Security Officer / MTF Agent | 8 | [#2] Dedicated protective detail (rotational guards/specialists); count chosen within 6–10 range and included in staff_wages. |
| On-site Emergency / Tactical Team Member | 10 | [#3] Rapid-response and specialized tactical team personnel (Sampi-5243 support); staffing implied by recurring emergency readiness costs. |
Confidence Notes
High uncertainty around reagent availability/cost (vim harenae), true scale/funding of Protocol GYRUS activations, and whether aggressive inhibition R&D or containment escalation will be pursued; many costs are program-level allocations rather than site-specific and therefore imprecise.